Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 390 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-central Nervous System Pathology Clear all
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 23, 2026, 10:14 AM EDT
Not listed No phase listed Observational

Study to Assess and Monitor Brain Activity

NCT04602988
View directory record Official record
Conditions
Delirium, Encephalopathy
Interventions
EEG
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 23, 2026, 10:14 AM EDT
Active, not recruiting Not applicable Interventional

Improving Access to Chiropractic Care in Community Health Centers

NCT06104605
View directory record Official record
Conditions
Lower Back Pain
Interventions
Institutional interventions, PCPs interventions, Patient interventions
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

ACP-103 to Treat Parkinson's Disease

NCT00086294
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias
Interventions
Intravenous Levodopa, ACP-103
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

NCT00004189
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, becatecarin, cisplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

EEG Cap for Identification of Non-Convulsive Status Epilepticus

NCT03138876
View directory record Official record
Conditions
Nonconvulsive Status Epilepticus, Subclinical Seizure, Altered Mental Status, Nonepileptic Seizures, Encephalopathy
Interventions
EEG Cap, Anti-seizure medication, Standard EEG
Device · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 4 Interventional

Istradefylline Effect Protocol on Parkinson's Disease Tremor

NCT05885360
View directory record Official record
Conditions
Parkinson Disease, Tremor
Interventions
Istradefylline Pill
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

NCT00750282
View directory record Official record
Conditions
Alzheimer Disease, Amyloid Beta-Protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
55 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Sun City, Arizona • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 23, 2026, 10:14 AM EDT
Suspended Phase 1 Interventional

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

NCT06677710
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions
IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
Indapta Therapeutics, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 23, 2026, 10:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078
View directory record Official record
Conditions
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions
Emavusertib, Ibrutinib
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Recruiting Phase 2 Interventional

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue

NCT05584124
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Decatur, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Completed No phase listed Observational

Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

NCT00897923
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer
Interventions
radionuclide imaging, indium In 111-labeled autologous peripheral blood mononuclear cells, indium In 111-labeled autologous polymorphonuclear leukocytes
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

NCT00019019
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

NCT01957735
View directory record Official record
Conditions
Metastatic Cancer, Cancer, Solid Tumor
Interventions
BP31510 monotherapy, BP31510 in combination with chemotherapy
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Sunnyvale, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Hyperbaric Oxygen for Traumatic and Non-traumatic Brain Injury

NCT01986205
View directory record Official record
Conditions
Brain Injury, Chronic
Interventions
Hyperbaric Oxygen, Minimal pressure air
Combination Product
Lead sponsor
Lindell Weaver
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 23, 2026, 10:14 AM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 4 Interventional

Antiplatelet Therapy to Prevent Stroke in African Americans

NCT00004727
View directory record Official record
Conditions
Stroke, Cerebral Infarction
Interventions
aspirin, ticlopidine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
29 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 10:14 AM EDT
Withdrawn No phase listed Observational

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

NCT05116618
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
InVisionFirst-Lung ctDNA assay
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1

NCT06462781
View directory record Official record
Conditions
Refractory Migraine
Interventions
Lidocaine hydrochloride, Methylprednisolone sodium succinate
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

Treating Primary Progressive Aphasia (PPA) Using tDCS

NCT04566731
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Transcranial Direct Current Stimulation (tDCS), Sham tDCS, Modified Contraint-Induced Language Therapy (mCILT)
Device · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 23, 2026, 10:14 AM EDT
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-Motor Features of Cervical Dystonia (CD)

NCT03471923
View directory record Official record
Conditions
Cervical Dystonia, Movement Disorders, Focal Dystonia, Signs and Symptoms, Nervous System Diseases, Neurologic Manifestations, Neuromuscular Manifestations, Spasmodic Torticollis
Interventions
Neurological Examination, Assessment of Non-Motor Features
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 23, 2026, 10:14 AM EDT